J

Johnson & Johnson

Makes prescription drugs and medical devices

Principal Data Engineer

Full-TimeUpdated on 10/23/2026
$102k - $170k
Expert
Bachelor's, Master's
New Brunswick, NJ, USA
Remote
Data & AnalyticsData Engineering

About the job

Requirements
  • A bachelor's degree in Computer Science, Engineering, Information Systems, Data Science, or a related field is required; a master's degree is preferred.
  • At least 15 years of experience in enterprise data engineering, technical architecture, analytics, AI platforms, and cloud engineering.
  • Proven experience leading architecture decisions, technical strategy, and engineering standards across multiple teams and products.
  • Hands-on expertise with Azure, Microsoft Fabric, Databricks, Power BI, and modern cloud-native technologies.
  • Strong experience with Data Mesh, Data Federation, Data Products, Data Modeling, Data Governance, and Enterprise Data Management disciplines.
  • Demonstrated expertise with Generative AI technologies, including large language models, retrieval-augmented generation, vector databases, AI agents, prompt engineering, and enterprise AI architectures.
  • Experience implementing MLOps, LLMOps, Responsible AI, model governance, and AI operationalization frameworks.
  • Strong understanding of structured and unstructured data architectures supporting enterprise AI and intelligent automation.
  • Experience leading the selection, implementation, integration, and operation of enterprise data, analytics, AI, and digital platforms.
  • Strong experience managing products and platforms throughout their lifecycle in complex, multi-team environments.
  • Deep understanding of enterprise delivery practices, including planning, dependency management, governance, compliance, quality management, and operational excellence.
  • Ability to align technology investments with business strategy, value drivers, and industry trends.
  • Strong understanding of cloud-native architectures, API-first design, distributed systems, and enterprise integration patterns.
  • Expertise with modern software development lifecycle practices, continuous integration and continuous delivery pipelines, test automation, DevOps, containerization, Infrastructure as Code, and platform engineering.
  • Exceptional communication, collaboration, and stakeholder management skills to influence technical and non-technical audiences.
  • Proven ability to lead through ambiguity and drive alignment across business and technology organizations.
Responsibilities
  • Lead the end-to-end data integration strategy for the Butterfly program, ensuring seamless data movement across customer relationship management, enterprise resource planning, master data management, customer data platforms, analytics, and downstream platforms.
  • Own integration architecture decisions, standards, and patterns across batch, real-time, API-based, event-driven, and file-based integrations.
  • Partner with business, product, and application teams to define data exchange requirements and align with enterprise data standards.
  • Drive the design, development, testing, and deployment of scalable integration solutions supporting global releases and country rollouts.
  • Establish and govern integration design reviews, technical specifications, mapping documents, and interface contracts.
  • Coordinate cross-functional teams to manage integration dependencies, risks, and release readiness.
  • Serve as the primary technical lead for application onboarding, source-to-target mapping, integration assessments, and data flow design.
  • Ensure integration solutions meet performance, reliability, scalability, security, and compliance requirements.
  • Design and implement enterprise integration solutions using APIs, ETL/ELT pipelines, messaging frameworks, event-driven architectures, and cloud-native integration patterns.
  • Lead source system onboarding and integration of commercial, customer, product, consent, and transactional data into Butterfly data products.
  • Establish reusable integration frameworks, canonical data models, and standardized mapping approaches to accelerate delivery and reduce complexity.
  • Embed data quality controls, reconciliation processes, exception handling, and monitoring capabilities into all integration solutions.
  • Collaborate with master data management, Data Product, Analytics, Experience, and Application teams to support a unified enterprise data ecosystem.
  • Define integration observability standards, including logging, alerting, monitoring, service-level agreement management, and operational support processes.
  • Drive API-first integration strategies and support the governance and lifecycle management of enterprise APIs and data services.
  • Lead migration and modernization efforts from legacy integrations to cloud-native architectures leveraging Azure, Databricks, and Microsoft Fabric.
  • Lead and influence technical teams across multiple squads, functions, geographies, and experience levels.
  • Coach, develop, and mentor engineering talent while promoting accountability, ownership, and innovation.
  • Establish trusted partnerships with architects, engineering leaders, product leaders, and business stakeholders.
Desired Qualifications
  • Experience operating in highly regulated industries with stringent security, privacy, compliance, and quality requirements.
  • Experience partnering with Information Security Risk Management, Quality & Compliance organizations, and audit functions to ensure operational readiness and control compliance.
  • Experience with enterprise knowledge management platforms, document intelligence solutions, and semantic technologies.
  • Familiarity with knowledge graphs, graph databases, vector platforms, enterprise search, and advanced AI retrieval strategies.
  • Demonstrated experience establishing engineering observability, reliability engineering practices, Site Reliability Engineering, and operational excellence frameworks.
  • Experience driving measurable business outcomes and value realization through enterprise data and AI initiatives.
  • Experience leading enterprise AI transformation programs, AI platform strategy, and adoption of emerging AI technologies at scale.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.